For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Restructuring and other charges | 309 | 1,435 | 1,983* | 812 |
| Research and development | 4,025 | 3,715 | 10,334* | 6,818 |
| General and administrative | 4,416 | 5,644 | 9,348* | 4,777 |
| Total operating expenses | 8,750 | 10,794 | 21,665 | 12,407 |
| Loss from operations | -8,750 | -10,794 | -21,665* | -12,407 |
| Other income, net | 4,708 | 785 | 1,282* | 412 |
| Investment income | 1,290 | 1,418 | 2,060* | 1,771 |
| Total other income, net | 5,998 | 2,203 | 3,342* | 2,183 |
| Loss before income taxes | -2,752 | -8,591 | -18,323* | -10,224 |
| Income tax expense | 15 | 28 | 122* | 10 |
| Net loss | -2,767 | -8,619 | -18,445* | -10,234 |
| Unrealized gain on marketable securities | - | - | 29* | - |
| Total comprehensive loss | - | - | -18,416 | - |
| Basic EPS | -0.06 | -0.18 | -0.382 | -0.21 |
| Diluted EPS | -0.06 | -0.18 | -0.382 | -0.21 |
| Basic Average Shares | 48,258,111 | 48,258,111 | 48,258,111 | 48,258,111 |
| Diluted Average Shares | 48,258,111 | 48,258,111 | 48,258,111 | 48,258,111 |
Ikena Oncology, Inc. (IKNA)
Ikena Oncology, Inc. (IKNA)